+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis Report By Type of Synthesis (Biotech, Synthetic), By Type of Manufacturer (Captive, Merchant), By Application, By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4761177
  • Report
  • 120 pages
  • Grand View Research
1 of 5

FEATURED COMPANIES

  • Abbvie, Inc.
  • Albemarle Corporation
  • Aurobindo Pharma
  • Cipla Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MORE
The global active pharmaceutical ingredient (API) market size is expected to reach at USD 268.12 billion by 2026 registering a CAGR of 6.8%, according to this report. Rising trend of outsourcing APIs and growing prevalence of various target diseases, such as cancer, Cardiovascular Disease (CVDs) are anticipated to boost the market. Huge capital is required in API production as the process needs extremely systematic protocols. Pharmaceutical companies can actually benefit from outsourcing API production, as it eliminates the need for installing expensive manufacturing units. Moreover, strategic outsourcing enables companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also estimated to drive the demand in future.

Growing geriatric population across the globe is also likely to contribute to the market expansion. Estimates published by the WHO suggest that the global base of population pertaining to the age group of 65 years and above is expected to rise from 7% in 2000 to 16% in 2050. Latin America, in particular, is projected to witness fastest growth, in terms of geriatric population, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%). Patent expiration of blockbuster drugs, growing outsourcing activities due to high manufacturing costs, and stringent regulations for API production are expected to intensify the market competition. As part of strategic geographic expansion, many companies are setting up manufacturing plants in the developing regions like Asia Pacific.

Further key findings from the study suggest:
  • Synthetic APIs held the largest share of the API market in 2018 owing to easy availability of raw materials and easier protocols for synthesis of these molecules
  • Biotech APIs are estimated to register the highest CAGR over the forecast years due to rising demand for biopharmaceuticals and higher efficiency of these molecules
  • Captive manufacturers led the market owing to intensive capitalization of major key players in development of high-end manufacturing facilities
  • Merchant manufacturers segment is expected to be the fastest-growing segment over the forecast period
  • Generic APIs are expected to register a lucrative CAGR over the forecast period on account of factors, such as expiration of patents of branded drugs and lower cost
  • Cardiology segment led the overall market in 2018. Increasing prevalence of target diseases worldwide and high demand for fast-acting drugs are some of the key factors responsible for the segment growth
  • North America held the largest market share in 2018. Asia Pacific is estimated to be the fastest-growing region expanding at a CAGR of 8.2% over the estimated period
  • Some of the major companies in the market are Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; Boehringer Ingelheim International GmbH; Cipla Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; Albemarle Corporation; Mylan N.V.; Aurobindo Pharma; Sun Pharmaceutical Industries Ltd.; and Dr. Reddy’s Laboratories Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie, Inc.
  • Albemarle Corporation
  • Aurobindo Pharma
  • Cipla Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MORE
Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Validation & Publishing
1.7 Geographic Scope & Assumptions
1.8 Region-Wise Market Calculation
1.8.1 Region-Wise Market: Base Estimates
1.9 Market CAGR Calculation
1.9.1 Region Based Segment Share Calculation

Chapter 2 Executive Summary
2.1 API Market Outlook
2.2 API Market: - Segment Outlook
2.3 API Market: -Competitive Insights
2.4 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping

Chapter 4 Market Dynamics
4.1 Market Driver Analysis
4.1.1 Growing Geriatric Population Base
4.1.2 Growing Prevalence Of Target Diseases Such As Hospital Acquired Infections, Genetic, Cardiovascular And Neurological Diseases
4.1.3 Increasing Preference For Targeted Therapy Approach In Cancer Treatment
4.1.4 Increasing Preference For Outsourcing APIs
4.2 Market Restraint Analysis
4.2.1 Large Capital Investments And Production Cost
4.2.2 Stringent Safety And Handling Regulations Regarding APIs

Chapter 5 API Market Analysis Tools
5.1 Industry Analysis - Porter’s
5.1.1 Supplier Power: Moderate Due To Large Number Of Diagnostic Test Manufacturers
5.1.2 Buyer Power: Moderate Due To Presence Of Players Entering Into Long-Term Contract
5.1.3 Substitution Threat: Low Due To No/ Less External Substitutes
5.1.4 Threat From New Entrant: Moderate Due To Brand Recognition Of The Existing Players
5.1.5 Competitive Rivalry: High Due To Increasing Mergers & Acquisitions By Major Players
5.2 PESTEL Analysis
5.2.1 Political Landscape
5.2.2 Environmental Landscape
5.2.3 Social Landscape
5.2.4 Technology Landscape
5.2.5 Legal Landscape
5.3 Major Deals & Strategic Alliances Analysis
5.3.1 Joint Ventures
5.3.2 Mergers & Acquisitions
5.3.3 Licensing & Partnership
5.3.4 Technology Collaborations
5.3.5 Strategic Divestments

Chapter 6 API Market - Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3 Public Companies
6.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)
6.3.2 Company Market Share/Ranking, By Region
6.3.3 Competitive Dashboard Analysis
6.3.4 Market Differentiators
6.3.5 Synergy Analysis: Major Deals & Strategic Alliances
6.4 Private Companies
6.4.1 List Of Key Emerging Companies
6.4.2 Regional Network Map
6.4.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)

Chapter 7 API Molecules Outlook
7.1 Global Sales (2014 - 2017)
7.2 Companies With Leading Market Position For API Molecules
7.2.1 Amoxicillin
7.2.2 Azithromycin
7.2.3 Bleomycin
7.2.4 Caspofungin
7.2.5 Clarithromycin
7.2.6 Clavulanic Acid
7.2.7 Clindamycin
7.2.8 Compactin (Mevastatin)
7.2.9 Cyclosporin
7.2.10 Dactinomycin
7.2.11 Daptomycin
7.2.12 Demeclocycline
7.2.13 Doxycycline
7.2.14 Erythromycin
7.2.15 Ivermectin (Avermectin)
7.2.16 Lovastatin
7.2.17 Micafungin
7.2.18 Minocycline
7.2.19 Mitomycin
7.2.20 Mycophenolic Acid
7.2.21 Pneumocandin B0
7.2.22 Polymyxin
7.2.23 Pravastatin
7.2.24 Rapamycin (Sirolimus)
7.2.25 Simvastatin
7.2.26 Steroids
7.2.27 Tacrolimus
7.2.28 Tetracycline
7.2.29 Tigecycline
7.2.30 Tobramycin
7.2.31 Vancomycin
7.3 Comparative Price Analysis Of The Above-Mentioned Molecules

Chapter 8 Type Of Synthesis Business Analysis
8.1. Definitions & Scope
8.2. Type of Synthesis Market Share Analysis, 2018 & 2026
8.3. API Market, by Type of Synthesis, 2014 to 2026
8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
8.5 Biotech API
8.5.1 Biotech API Market, 2014 - 2026 (USD Billion)
8.5.2 Monoclonal Antibodies
8.5.2.1 Monoclonal Antibodies Market, 2014 - 2026 (USD Billion)
8.5.3 Recombinant Proteins
8.5.3.1 Recombinant Proteins Market, 2014 - 2026 (USD Billion)
8.5.4 Vaccines
8.5.4.1 Vaccines Market, 2014 - 2026 (USD Billion)
8.6 Synthetic API
8.6.1 Synthetic API Market, 2014 - 2026 (USD Billion)

Chapter 9 Type Of Manufacturer Business Analysis
9.1. Definitions & Scope
9.2. Type of Manufacturer Market Share Analysis, 2018 & 2026
9.3. API Market, by Type of Manufacturer, 2014 to 2026
9.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
9.5 Captive API
9.5.1 Captive API Market, 2014 - 2026 (USD Billion)
9.6 Merchant API
9.6.1 Merchant API Market, 2014 - 2026 (USD Billion)

Chapter 10 Type Business Analysis
10.1. Definitions & Scope
10.2. Type Market Share Analysis, 2018 & 2026
10.3. API Market, by Type, 2014 to 2026
10.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
10.5 Generic APIs
10.5.1 Generic API Market, 2014 - 2026 (USD Billion)
10.6 Innovative APIs
10.6.1 Innovative API Market, 2014 - 2026 (USD Billion)

Chapter 11 Application Business Analysis
11.1. Definitions & Scope
11.2. Application Market Share Analysis, 2018 & 2026
11.3. API Market, by Application, 2014 to 2026
11.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
11.5 Cardiology
11.5.1 Cardiology Market, 2014 - 2026 (USD Billion)
11.6 Oncology
11.6.1 Oncology Market, 2014 - 2026 (USD Billion)
11.7 Cns & Neurology
11.7.1 Cns & Neurology Market, 2014 - 2026 (USD Billion)
11.8 Orthopedics
11.8.1 Orthopedics Market, 2014 - 2026 (USD Billion)
11.9 Endocrinology
11.9.1 Endocrionology Market, 2014 - 2026 (USD Billion)
11.10 Pulmonology
11.10.1 Pulmonology Market, 2014 - 2026 (USD Billion)
11.11 Gastroenterology
11.11.1 Gastrointestinal Disorders Market, 2014 - 2026 (USD Billion)
11.12 Nephrology
11.12.1 Nephrology Market, 2014 - 2026 (USD Billion)
11.13 Ophthalmology
11.13.1 Opthalmology Market, 2014 - 2026 (USD Billion)
11.14 Others
11.14.1 Others Market, 2014 - 2026 (USD Billion)

Chapter 12 Application, By Type Business Analysis (Cross-Matrix)
12.1. Definitions & Scope
12.2. Application Market Share Analysis, 2018 & 2026
12.3. API Market, by Application, 2014 to 2026
12.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
12.5 Cardiology
12.5.1 Generic
12.5.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.5.2 Innovative
12.5.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.6 Oncology
12.6.1 Generic
12.6.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.6.2 Innovative
12.6.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.7 CNS & Neurology
12.7.1 Generic
12.7.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.7.2 Innovative
12.7.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.8 Orthopedics
12.8.1 Generic
12.8.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.8.2 Innovative
12.8.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.9 Endocrinology
12.9.1 Generic
12.9.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.9.2 Innovative
12.9.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.10 Pulmonology
12.10.1 Generic
12.10.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.10.2 Innovative
12.10.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.11 Gastroenterology
12.12.1 Generic
12.12.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.12.2 Innovative
12.12.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.12 Nephrology
12.12.1 Generic
12.12.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.12.2 Innovative
12.12.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.13 Ophthalmology
12.13.1 Generic
12.13.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.13.2 Innovative
12.13.2.1 Innovative Market, 2014 - 2026 (USD Billion)
12.14 Others
12.14.1 Generic
12.14.1.1 Generic Market, 2014 - 2026 (USD Billion)
12.14.2 Innovative
12.14.2.1 Innovative Market, 2014 - 2026 (USD Billion)

Chapter 13 API Market: Regional Estimates & Trend Analysis
13.1. Definitions & Scope
13.2. Application Market Share Analysis, 2018 & 2026
13.3. API Market, by Application, 2014 to 2026
13.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
13.5 North America.
13.5.1 north america market estimates and forecast, 2014 - 2026
13.5.2 U.S.
13.5.2.1 U.S. market estimates and forecast, 2014 - 2026
13.5.3 Canada
13.5.3.1 Canada market estimates and forecast, 2014 - 2026
13.6 Europe
13.6.1 Europe market estimates and forecast, 2014 - 2026
13.6.2 Germany
13.6.2.1 Germany market estimates and forecast, 2014 - 2026
13.6.3 U.K.
13.6.3.1 U.K. market estimates and forecast, 2014 - 2026
13.6.4 Spain
13.6.4.1 Spain market estimates and forecast, 2014 - 2026
13.6.5 France
13.6.5.1 France market estimates and forecast, 2014 - 2026
13.6.6 Italy
13.6.6.1 Italy market estimates and forecast, 2014 - 2026
13.7 Asia-Pacific
13.7.1 Asia-Pacific market estimates and forecast, 2014 - 2026
13.7.2 Japan
13.7.2.1 Japan market estimates and forecast, 2014 - 2026
13.7.3 China
13.7.3.1 China market estimates and forecast, 2014 - 2026
13.7.4 India
13.7.4.1 India market estimates and forecast, 2014 - 2026
13.7.5 South Korea
13.7.5.1 South Korea market estimates and forecast, 2014 - 2026
13.7.6 Australia
13.7.6.1 Australia market estimates and forecast, 2014 - 2026
13.8 Latin America
13.8.1 Latin America market estimates and forecast, 2014 - 2026
13.8.2 Brazil
13.8.2.1 Brazil market estimates and forecast, 2014 - 2026
13.8.3 Mexico
13.8.3.1 Mexico Market estimates and forecast, 2014 - 2026
13.8.4 Argentina
13.8.4.1 Argentina Market estimates and forecast, 2014 - 2026
13.9 Middle East and Africa
13.9.1 Middle-East and Africa market estimates and forecast, 2014 - 2026
13.9.2 South Africa
13.9.2.1 South Africa market estimates and forecast, 2014 - 2026
13.10.SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
13.10.1. North America
13.10.2. Europe
13.10.3. Asia Pacific
13.10.4. Latin America
13.10.5. Middle East & Africa

Chapter 14 Competitive Landscape
14.1 Company Profiles
14.1.1 ABBVIE, INC.
14.1.1.1 Company overview
14.1.1.2 Financial performance
14.1.1.3 Product benchmarking
14.1.1.4 Strategic initiatives
14.1.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.2.1 Company overview
14.1.2.2 Financial performance
14.1.2.3 Product benchmarking
14.1.2.4 Strategic initiatives
14.1.3 BRISTOL-MYERS SQUIBB COMPANY
14.1.3.1 Company overview
14.1.3.2 Financial performance
14.1.3.3 Product benchmarking
14.1.3.4 Strategic initiatives
14.1.4 CIPLA INC.
14.1.4.1 Company overview
14.1.4.2 Financial performance
14.1.4.3 Product benchmarking
14.1.4.4 Strategic initiatives
14.1.5 MERCK & CO., INC.
14.1.5.1 Company overview
14.1.5.2 Financial performance
14.1.5.3 Product benchmarking
14.1.5.4 Strategic initiatives
14.1.6 ALBEMARLE CORPORATION
14.1.6.1 Company overview
14.1.6.2 Financial overview
14.1.6.3 Product benchmarking
14.1.6.4 Strategic initiatives
14.1.7 AUROBINDO PHARMA
14.1.7.1 Company overview
14.1.7.2 Financial overview
14.1.7.3 Product benchmarking
14.1.7.4 Strategic initiatives
14.1.8 MYLAN N.V.
14.1.8.1 Company overview
14.1.8.2 Financial overview
14.1.8.3 Product benchmarking
14.1.8.4 Strategic initiatives
14.1.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.1.9.1 Company overview
14.1.9.2 Financial overview
14.1.9.3 Product benchmarking
14.1.9.4 Strategic initiatives
14.1.10 SUN PHARMACEUTICAL INDUSTRIES, LTD.
14.1.10.1 Company overview
14.1.10.2 Financial overview
14.1.10.3 Product benchmarking
14.1.10.4 Strategic initiatives
14.1.11 DR. REDDY’S LABORATORIES LTD.
14.1.11.1 Company overview
14.1.11.2 Financial overview
14.1.11.3 Product benchmarking
14.1.11.4 Strategic initiative

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie, Inc.
  • Boehringer Ingelheim International Gmbh
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Merck & Co., Inc.
  • Albemarle Corporation
  • Aurobindo Pharma
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries, Ltd.
  • Dr. Reddy’S Laboratories Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4761177
Adroll
adroll